Late mortality in pediatric patients with craniopharyngioma

Johannes Visser1, Juliette Hukin, Michael Sargent

  • 1Children's Hospital, Leicester Royal Infirmary, Leicester, LE1 5WW, UK.

Insights

Pediatric craniopharyngioma patients face long-term mortality risks beyond ten years post-diagnosis. Late deaths are multifactorial, rarely due to disease progression, necessitating lifelong follow-up.

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Endocrinology

Background:

  • Craniopharyngioma survival rates vary significantly, with some pediatric patients dying more than 10 years after diagnosis.
  • Long-term outcomes and causes of late mortality in pediatric craniopharyngioma are not well-defined.

Purpose of the Study:

  • To investigate the causes and timing of death in pediatric craniopharyngioma patients.
  • To report overall survival rates in a population-based cohort.

Main Methods:

  • Retrospective chart review of pediatric patients (<17 years) diagnosed with craniopharyngioma in British Columbia (1967-2003).
  • Inclusion of deaths reported to a central agency, capturing patients lost to clinical follow-up.
  • Neuroradiologist review of imaging studies.

Main Results:

  • Nine deaths occurred among 41 patients, with four deaths happening >10 years post-diagnosis (23% of those followed >10 years).
  • Causes of late mortality included progressive disease, diabetes insipidus, panhypopituitarism, infarction, and unexplained events.
  • Ten-year overall survival was 84.1%; 20-year overall survival was 76.5%.

Conclusions:

  • Pediatric craniopharyngioma survivors are at risk of premature death more than 10 years after diagnosis.
  • Late mortality is multifactorial, infrequently linked to direct disease progression.
  • Lifelong follow-up and novel treatment strategies are essential for managing craniopharyngioma.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Increased Intracranial Pressure ll: Pathophysiology01:29

Increased Intracranial Pressure ll: Pathophysiology

Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins with...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Increased Intracranial Pressure l: Introduction01:14

Increased Intracranial Pressure l: Introduction

Intracranial hypertension is a sustained elevation of intracranial pressure (ICP) above 22 mm Hg. In supine adults, normal ICP is ~7–15 mm Hg.The rigid, nonexpandable cranium contains three components—brain tissue, blood, and cerebrospinal fluid (CSF)—that total ~1,700 mL in a typical adult: 1,400 mL brain (~80%), 150 mL blood (~10%), and 150 mL CSF (~10%). According to the Monro–Kellie doctrine, total intracranial volume is effectively fixed. When one component expands, CSF and venous blood...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...